Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors

Published:2021-04-09 Issue:4 Volume:3 Page:234-240
ISSN:2434-0790
Container-title:Circulation Reports
language:en
Short-container-title:Circ Rep

Author:

Kadowaki Hiroshi¹,Ishida Junichi¹,Akazawa Hiroshi¹,Yagi Hiroki¹,Saga-Kamo Akiko¹,Umei Masahiko¹,Matsuoka Ryo¹,Liu Qing¹,Matsunaga Hiroshi¹,Maki Hisataka¹,Sato Yusuke²,Kume Haruki²,Komuro Issei¹

Affiliation:

1. Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo

2. Department of Urology, Graduate School of Medicine, The University of Tokyo

Publisher

Japanese Circulation Society

Subject

Marketing,Organizational Behavior and Human Resource Management,Strategy and Management,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/circrep/3/4/3_CR-21-0008/_pdf

Reference24 articles.

1. 1. Jain M, Townsend RR. Chemotherapy agents and hypertension: A focus on angiogenesis blockade. Curr Hypertens Rep 2007; 9: 320–328.

2. 2. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010; 102: 14–25.

3. 3. Katsi V, Magkas N, Georgiopoulos G, Athanasiadi E, Virdis A, Masi S, et al. Arterial hypertension in patients under antineoplastic therapy: A systematic review. J Hypertens 2019; 37: 884–901.

4. 4. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers 2017; 3: 17009.

5. 5. Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies: Focus on hypertension and arterial thrombotic events. J Am Soc Hypertens 2018; 12: 409–425.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic hypertension with VEGFR inhibitor (axitinib) therapy in cancer patients: A meta-analysis and systematic review of randomized controlled trials;IJC Heart & Vasculature;2024-06

2. Role of endothelin ETA receptors in the hypertension induced by the VEGFR-2 kinase inhibitors axitinib and lenvatinib in conscious freely-moving rats;Biochemical Pharmacology;2023-12

3. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma;The Oncologist;2023-01-01

4. Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma;Clinical Drug Investigation;2022-06-13

5. Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data;Frontiers in Cardiovascular Medicine;2022-03-15